{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T13:03:34Z","timestamp":1793192614880,"version":"4.5.0"},"reference-count":30,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Sodium-glucose co-transporter 2 (SGLT2) inhibitors such as dapagliflozin and empagliflozin are increasingly used in heart failure (HF) management due to their cardiovascular benefits. However, glycosuria induced by SGLT2 inhibition may increase the risk of urinary tract infections (UTIs). Limited data exist on UTI burden among HF patients on SGLT2 inhibitors in low-resource settings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study aimed to determine the prevalence of UTIs, associated factors, and antimicrobial susceptibility patterns of uropathogens in HF patients receiving SGLT2 inhibitors at the Jakaya Kikwete Cardiac Institute (JKCI) in Tanzania.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A hospital-based cross-sectional study was conducted from March to June 2024 among HF patients aged \u226518 years on SGLT2 inhibitors. Data was collected using structured questionnaires and medical records. Midstream clean-catch urine samples were collected in sterile containers and processed using semi-quantitative urine culture on CLED and blood agar and subjected to antimicrobial susceptibility testing using the Kirby-Bauer disk diffusion method per CLSI M100 (2024) guidelines. Descriptive statistics and modified Poisson regression were used for analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Out of 138 urine samples processed, 22 (15.9%) showed significant growth. The most common uropathogen was\n                      <jats:italic>Escherichia coli<\/jats:italic>\n                      (50.0%), followed by\n                      <jats:italic>Klebsiella pneumoniae<\/jats:italic>\n                      (13.6%),\n                      <jats:italic>Pseudomonas aeruginosa<\/jats:italic>\n                      (9.1%), and\n                      <jats:italic>Candida<\/jats:italic>\n                      spp. (9.1%). Significant risk factors for UTI included age\u2009&gt;\u200960 years (aPR 3.77; 95% CI: 1.42\u201310.01), female sex (aPR 2.92; 95% CI: 1.19\u20137.15), and SGLT2 inhibitor use\u2009\u2265\u20094 months (aPR 3.19; 95% CI: 1.70\u20135.96). High resistance was observed among bacterial isolates against ampicillin (100%), tetracycline (69.2%), and ceftazidime (53.8%), whereas high susceptibility was noted against nitrofurantoin (84.6%) and meropenem (100%).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec005\">\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>UTIs are common among HF patients on SGLT2 inhibitors, with E. coli as the predominant pathogen and a concerning resistance to commonly used antibiotics. These findings underscore the need for routine urine culture and sensitivity testing to guide appropriate therapy and promote antimicrobial stewardship, particularly in resource-constrained settings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0344986","type":"journal-article","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T17:26:01Z","timestamp":1774545961000},"page":"e0344986","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":2,"title":["Urinary tract infections, risk factors and antimicrobial resistance patterns in heart failure patients on sodium-glucose transporter 2 inhibitors: Evidence from Jakaya Kikwete Cardiac Institute in Tanzania"],"prefix":"10.1371","volume":"21","author":[{"given":"Julieth","family":"Kaaya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6118-1560","authenticated-orcid":true,"given":"Martine A.","family":"Manguzu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deus","family":"Buma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamu","family":"Mlyuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samwel","family":"Rweyemamu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Ntukula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helfrid B.","family":"Ilomo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias","family":"Bukundi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6574-5308","authenticated-orcid":true,"given":"Raphael","family":"Sangeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8963-4920","authenticated-orcid":true,"given":"Ritah F.","family":"Mutagonda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,3,26]]},"reference":[{"key":"pone.0344986.ref001","doi-asserted-by":"crossref","first-page":"777861","DOI":"10.3389\/fmed.2021.777861","article-title":"Sodium-glucose cotransporter 2 inhibitors mechanisms of action: A Review","volume":"8","author":"JI Fonseca-Correa","year":"2021","journal-title":"Front Med (Lausanne)"},{"issue":"5","key":"pone.0344986.ref002","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1093\/cvr\/cvae047","article-title":"SGLT2 inhibitors: from glucose-lowering to cardiovascular benefits","volume":"120","author":"A Preda","year":"2024","journal-title":"Cardiovasc Res"},{"issue":"4","key":"pone.0344986.ref003","doi-asserted-by":"crossref","first-page":"262","DOI":"10.7326\/0003-4819-159-4-201308200-00007","article-title":"Sodium\u2013glucose cotransporter 2 inhibitors for type 2 diabetes","volume":"159","author":"D Vasilakou","year":"2013","journal-title":"Ann Intern Med"},{"issue":"2","key":"pone.0344986.ref004","doi-asserted-by":"crossref","first-page":"198","DOI":"10.33963\/KP.a2021.0172","article-title":"SGLT2 inhibitors and the risk of urinary tract infections in patients with heart failure: A pooled analysis examining safety endpoints","volume":"80","author":"JA Borovac","year":"2022","journal-title":"Kardiol Pol"},{"issue":"2","key":"pone.0344986.ref005","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1002\/ehf2.13793","article-title":"Susceptibility to infections and adaptive immunity in adults with heart failure","volume":"9","author":"U Salzer","year":"2022","journal-title":"ESC Heart Fail"},{"issue":"1","key":"pone.0344986.ref006","article-title":"Impact of infection-related admission in patients with heart failure: a 10 years national cohort study","volume":"13","author":"CY Chen","year":"2023","journal-title":"Sci Rep"},{"issue":"4","key":"pone.0344986.ref007","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1161\/CIRCULATIONAHA.120.050391","article-title":"Efficacy of dapagliflozin on renal function and outcomes in patients with heart failure with reduced ejection fraction: results of DAPA-HF","volume":"143","author":"PS Jhund","year":"2021","journal-title":"Circulation"},{"issue":"2","key":"pone.0344986.ref008","doi-asserted-by":"crossref","DOI":"10.1097\/XCE.0000000000000284","article-title":"Safety outcomes of sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes and other risk factors for cardiovascular disease: a systematic review and meta-analysis","volume":"12","author":"R Deshpande","year":"2023","journal-title":"Cardiovasc Endocrinol Metab"},{"issue":"1","key":"pone.0344986.ref009","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1186\/s12874-022-01694-7","article-title":"Sample size calculation for prevalence studies using Scalex and ScalaR calculators","volume":"22","author":"L Naing","year":"2022","journal-title":"BMC Med Res Methodol"},{"key":"pone.0344986.ref010","volume-title":"District laboratory practice in tropical countries, part 2 second edition","author":"M Cheesbrough"},{"key":"pone.0344986.ref011","volume-title":"Performance standards for antimicrobial susceptibility testing","author":"Clinical and Laboratory Standards Institute","year":"2024","edition":"34"},{"issue":"2","key":"pone.0344986.ref012","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1097\/JU.0000000000001383","article-title":"Warmer Weather and the Risk of Urinary Tract Infections in Women","volume":"205","author":"JE Simmering","year":"2021","journal-title":"J Urol"},{"key":"pone.0344986.ref013","article-title":"United republic of tanzania 12 international monetary fund a","author":"International Monentary Fund","journal-title":"Stylized Facts of Climate Change Trends"},{"issue":"3","key":"pone.0344986.ref014","doi-asserted-by":"crossref","DOI":"10.1128\/msphere.00004-22","article-title":"Glycosuria alters uropathogenic escherichia coli global gene expression and virulence","volume":"7","author":"MJ Islam","year":"2022","journal-title":"mSphere"},{"key":"pone.0344986.ref015","doi-asserted-by":"crossref","first-page":"1756287218814382","DOI":"10.1177\/1756287218814382","article-title":"Risk factors and predisposing conditions for urinary tract infection","volume":"11","author":"O Storme","year":"2019","journal-title":"Ther Adv Urol"},{"issue":"1","key":"pone.0344986.ref016","article-title":"Frequency of urinary tract infections in type 2 diabetic patients taking dapagliflozin","volume":"14","author":"S Khan","year":"2022","journal-title":"Cureus"},{"issue":"1","key":"pone.0344986.ref017","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.910","article-title":"Risk of genital and urinary tract infections associated with SGLT-2 inhibitors as an add-on therapy to metformin in patients with type 2 diabetes mellitus: A retrospective cohort study in Korea","volume":"10","author":"H Yang","year":"2022","journal-title":"Pharmacol Res Perspect"},{"issue":"1","key":"pone.0344986.ref018","first-page":"40","article-title":"Urinary tract infection in women","volume":"20","author":"K Czajkowski","year":"2021","journal-title":"Prz Menopauzalny"},{"key":"pone.0344986.ref019","doi-asserted-by":"crossref","DOI":"10.3390\/ph16071031","article-title":"Lower urinary tract disorders as adverse drug reactions\u2014A literature review","volume":"16","author":"L Dobrek","year":"2023","journal-title":"Pharmaceuticals"},{"key":"pone.0344986.ref020","doi-asserted-by":"crossref","first-page":"100082","DOI":"10.1016\/j.deman.2022.100082","article-title":"Incidence and factors associated with genitourinary infections among Type 2 diabetes patients on SGLT2 Inhibitors: A single retrospective cohort study","volume":"7","author":"MKC Caro","year":"2022","journal-title":"Diabetes Epidemiology and Management"},{"issue":"12","key":"pone.0344986.ref021","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1007\/s40264-020-01010-6","article-title":"Potential safety issues with use of sodium-glucose cotransporter 2 inhibitors, particularly in people with type 2 diabetes and chronic kidney disease","volume":"43","author":"TY Milder","year":"2020","journal-title":"Drug Saf"},{"issue":"12","key":"pone.0344986.ref022","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3390\/medicines9120059","article-title":"The incidence and risk factors of urinary tract infection in patients with type 2 diabetes mellitus using SGLT2 inhibitors: a real-world observational study","volume":"9","author":"S Uitrakul","year":"2022","journal-title":"Medicines"},{"issue":"5","key":"pone.0344986.ref023","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/nrmicro3432","article-title":"Urinary tract infections: epidemiology, mechanisms of infection and treatment options","volume":"13","author":"AL Flores-Mireles","year":"2015","journal-title":"Nat Rev Microbiol"},{"issue":"1","key":"pone.0344986.ref024","doi-asserted-by":"crossref","first-page":"270","DOI":"10.4314\/ahs.v23i1.29","article-title":"Prevalence of genitourinary infection in diabetic patients treated with SGLT 2 inhibitors","volume":"23","author":"A Shrikrishna","year":"2023","journal-title":"Afr Health Sci"},{"issue":"1","key":"pone.0344986.ref025","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1186\/s12879-023-08641-x","article-title":"Prevalence of urinary tract infection and antimicrobial resistance patterns of uropathogens with biofilm forming capacity among outpatients in morogoro, Tanzania: a cross-sectional study","volume":"23","author":"EM Mlugu","year":"2023","journal-title":"BMC Infect Dis"},{"issue":"12","key":"pone.0344986.ref026","doi-asserted-by":"crossref","DOI":"10.3390\/antibiotics11121718","article-title":"Multidrug-resistant uropathogens causing community acquired urinary tract infections among patients attending health facilities in Mwanza and Dar es Salaam, Tanzania","volume":"11","author":"V Silago","year":"2022","journal-title":"Antibiotics"},{"key":"pone.0344986.ref027","author":"Tanzania Medicine and Medical Devices Authority"},{"issue":"9","key":"pone.0344986.ref028","doi-asserted-by":"crossref","first-page":"630","DOI":"10.3390\/antibiotics9090630","article-title":"Current antibiotic resistance trends of uropathogens in central europe: survey from a tertiary hospital urology department 2011-2019","volume":"9","author":"J Hrbacek","year":"2020","journal-title":"Antibiotics (Basel)"},{"key":"pone.0344986.ref029","first-page":"1","article-title":"Predominance of multidrug-resistant (MDR) bacteria causing urinary tract infections (UTIs) among symptomatic patients in East Africa: a call for action","author":"AA Maldonado-barrag\u00e1n","year":"2023"},{"issue":"4","key":"pone.0344986.ref030","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.4314\/ahs.v16i4.31","article-title":"Factors associated with community-acquired urinary tract infections among adults attending assessment centre, Mulago Hospital Uganda","volume":"16","author":"D Kabugo","year":"2016","journal-title":"Afr Health Sci"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0344986","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T17:26:15Z","timestamp":1774545975000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0344986"}},"subtitle":[],"editor":[{"given":"Tombari Pius","family":"Monsi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,3,26]]},"references-count":30,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3,26]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0344986","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,26]]}}}